Raymond James downgrades Doximity stock rating on weak growth outlook By Investing.com

Raymond James downgraded Doximity to Outperform from Strong Buy and cut its price target to $23 from $40 after fiscal 2027 guidance called for just 4% growth, below the Street’s 8% expectation. Doximity’s fiscal Q4 2026 revenue rose 5.1% to $145.4 million, modestly ahead of estimates, but adjusted EBITDA fell 5.6% year over year and multiple firms cited weak visibility and AI monetization timing risks. The stock trades at $23.39, about 61% below its level a year ago, and analysts broadly remain cautious on near-term growth.

Analysis

The key issue is not the quarter; it’s that the market is being told the recovery is a fiscal-2028 story, which pushes out any multiple re-rating and raises the bar for AI monetization. That matters because DOCS has likely already moved from being valued as a growth compounder to a “prove it” cash-flow name, so each incremental miss in top-line acceleration has an outsized impact on terminal multiple assumptions.

Second-order, this weakens the investment case for adjacent digital-health and ad-tech vendors that were implicitly being priced off a faster enterprise sales cycle in healthcare. If a category leader with strong practitioner engagement can’t translate product improvements into near-term acceleration, smaller point-solution peers will likely face longer sales cycles, higher CAC, and more scrutiny on AI ROI. That can also pressure broader healthcare software multiples as investors stop paying for “AI optionality” unless there is a clear monetization path.

The selloff may still be partly overdone tactically because expectations have already compressed sharply and the stock is now trading near levels that assume little execution success. But the stock likely needs two things before it can re-rate: evidence that search/AI products lift ARPU or retention within the next 2-3 quarters, and proof that margins stabilize despite slower growth. Absent that, the setup is a sideways-to-lower grinder rather than a sharp collapse.

The main bull case is that consensus may be underestimating the lag between product launch and monetization, not the eventual size of the opportunity. If AI workflow tools improve physician engagement or ad conversion rates, the operating leverage could show up quickly once the cycle turns; however, that is a late-2026 to 2027 earnings story, not a near-term catalyst. Until then, the stock behaves more like a duration trade than a fundamental compounder.

Key Decisions for Investors

• Short DOCS on strength over the next 1-2 weeks; use rallies toward the low-mid $20s as entry. Risk/reward favors a grind lower if the market starts discounting fiscal-2028 upside instead of fiscal-2027 recovery.
• For existing longs, reduce exposure and replace with a defined-risk call spread only if you want AI optionality without full downside. Consider 6-9 month upside structures rather than outright shares, since catalyst timing is delayed.
• Pair trade: short DOCS / long a higher-quality healthcare software name with clearer near-term monetization and margin visibility. The relative trade should benefit if investors keep demanding proof of AI revenue conversion.
• Avoid chasing dip buys until there is evidence in one of the next 1-2 quarters that AI products are contributing to revenue mix or gross margin expansion. Without that, the stock is likely to remain range-bound with negative skew.